Keeping up to date with advances in comprehensive ophthalmology and in the ophthalmic sub-specialties is extremely difficult because of the accelerating rapidity with which new information and technology become available and the diminishing time and opportunity for practitioners and trainees to read and learn. The first edition of Albert and Jakobiec’s Principles and Practice (1994) was conceived with the idea of utilizing an electronic, updated version in which the chapters were revised by the chapter authors on an annual or semi-annual basis, but the technology was not sufficiently advanced to achieve this goal. Subsequent editions (2000 and 2008) were organized by Saunders and the last published by Elsevier (of which Springer has obtained the complete rights to move forward with the 4^th edition).

For nearly three decades, this text has provided its readers with authoritative and comprehensive coverage of clinical ophthalmology, written and edited by a group of authors who represented a “Who’s Who” in ophthalmology. By using Springer’s Meteor platform, with its ability to allow authors and editors access to updating their chapters online annually/semi-annually, and with the recruitment of select chapter authors, this work’s usefulness as the standard text in ophthalmology will be maintained and expanded upon by Springer.

The 4^th edition of this comprehensive and authoritative text is written by hundreds of the most distinguished authorities from around the world and edited by four leaders in the field, providing today's best answers to every question that arises in ophthalmology practice. Richly illustrated with thousands of high quality, full color, clinically-relevant images, Albert and Jakobiec's Principles and Practice of Ophthalmology, 4th Edition covers every scientific and clinical principle in ophthalmology, ensuring that the reader will always be able to find the guidance needed to diagnose and manage patients' ocular problems and meet today's standards of care. Written for practicing ophthalmologists and trainees, this book delivers in-depth guidance on new diagnostic approaches, operative techniques, and treatment options, as well as coherent explanations of new scientific concept and its clinical importance. The 4^th edition will prove to be the source every practicing clinician needs to efficiently and confidently overcome any clinical challenge they may face.

Updates include new chapters on anterior and posterior segment diseases, as well as chapters more focused on treatment, plus thousands of new, high-quality, color images and illustrations, updated references, and information on the most cutting-edge technology used by clinicians in their practices today. Additionally, readers will enjoy the same, user-friendly, full-color design they remember from the previous edition, complete with many at-a-glance summary tables, algorithms, boxes, and diagrams that allow the reader to locate the assistance needed more rapidly than ever.

Acerca del autor

Dr. Daniel M. Albert is an American ophthalmologist, ophthalmic pathologist, and ocular cancer researcher. He is presently Professor of Ophthalmology at the Casey Eye Institute, Oregon Health and Science University. Dr. Albert earned his medical degree and completed a residency in ophthalmology at the University of Pennsylvania, following which he was a research fellow at the NIH and then an NIH special fellow in ophthalmic pathology at the Armed Forces Institute of Pathology. He assumed his first academic faculty position at Yale University (1969-76), rising to full professor at the Yale Medical School. He then served as Associate Surgeon at the Massachusetts Eye and Infirmary, where he worked with Dr. David G. Cogan and subsequently directed the hospital’s Cogan Eye Pathology Laboratory. He was Professor of Ophthalmology at Harvard (1976-83) and held that university’s Cogan Professorship in Ophthalmology (1983-92).

In 1992, Dr. Albert was appointed Chair of theDepartment of Ophthalmology and Visual Sciences and the Frederick A. Davis Professor at the University of Wisconsin School of Medicine and Public Health. He was the founding Director of the University of Wisconsin’s McPherson Eye Research Institute, a position he held for ten years, until he moved to Portland, Oregon in 2016 to assume his current position. During his career Dr. Albert has additionally held visiting appointments across the United States as well as at the University of London and the Institute of Ophthalmology at Moorfields Eye Hospital and has been a guest lecturer in France and Japan.

Dr. Albert’s research has focused on ocular tumors, particularly melanoma and retinoblastoma. He has published over 700 peer-reviewed journal articles and is the author or co-author of forty texts and monographs. The great majority are in the field of ocular cancer. He served for twenty years as Editor-in-Chief of the Archives of Ophthalmology (now JAMA Ophthalmology) and on the editorial board of nine academic journals including the Journal of the American Medical Association (JAMA) and Ophthalmology (from 2013 to the present). He also wrote a series of blog posts for the journal Science between 2009 and 2013, offering career advice to students considering a career in medicine.

Dr. Albert was awarded the degree Doctor Honoris Causa from the Universite Louis Pasteur in France in 1984 and also received honorary degrees from Harvard Medical School (1976) and the Yale School of Medicine (2019). He received the Best Medical Book Award for the 1994 (first) edition of Principles and Practice of Ophthalmology from the Association of American Publishers. In 2001, he received the University of Pennsylvania School of Medicine’s Distinguished Graduate Award. In 2008 he was recognized with the creation of The Daniel M. Albert Professorship in Visual Sciences established by the University of Wisconsin School of Medicine and Public Health. In 2011 he was named Laureate of the American Academy of Ophthalmology, the society’s highest honor. Dr. Albert has received numerous other awards, including the Albert C. Muse Prize, Association for Research and Vision’s Friedenwald Award, Humboldt Research Award, American Ophthalmological Society’s Lucien Howe Medal, Pisart Vision Award and the American Association of Ocular Pathologists’ Zimmerman Medal. Dr. Albert served as a director on the American Board of Ophthalmology (1997-2005), Vice-President of ARVO, and President of the American Ophthalmological Society (2005-6).

Joan W. Miller is the David Glendenning Cogan Professor and Chair of the Department of Ophthalmology at Harvard Medical School (HMS), Chief of Ophthalmology at Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women’s Hospital. A graduate of Massachusetts Institute of Technology (MIT), she earned her MD from HMS and completed her ophthalmology residency and vitreoretinal fellowship at Mass Eye and Ear. In 2002, Dr. Miller became the first female physician to achieve the rank of Professor of Ophthalmology at HMS, and in 2003, the first woman to serve as Chair of the Department of Ophthalmology. She is also the first woman appointed as Chief of Ophthalmology at both Mass Eye and Ear and Mass General Hospital.

Her clinical research interests focus on retinal disorders, including age-related macular degeneration (AMD). Dr. Miller and her colleagues at Mass Eye and Ear/HMS pioneered the development of verteporfin photodynamic therapy (Visudyne�), the first pharmacologic therapy for AMD. The group also identified the key role of vascular endothelial growth factor (VEGF) in ocular neovascularization, leading to the development of anti-VEGF therapies now administered to millions of people with sight-threatening retinal diseases annually around the world. Her current studies focus on the pathogenesis of AMD, including genomics, metabolomics, imaging, and functional measures; strategies for early intervention in AMD; and neuroprotective therapies for retinal diseases.

An internationally recognized expert in the field of retina, Dr. Miller has published over 280 original articles and more than 95 book chapters, reviews, and editorials. A member of the National Academy of Medicine and the Academia Ophthalmologica Internationalis, she has received numerous honors for her work. Among them, Dr. Miller delivered the 2012 Edward Jackson Lecture for the American Academy of Ophthalmology (AAO), and was a co-recipient of the 2014 Ant�nio Champalimaud Vision Award, the highest distinction in ophthalmology and visual science. In 2015, Dr. Miller became the first woman to receive the Mildred Weisenfeld Award for Excellence in Ophthalmology from Association for Research in Vision and Ophthalmology (ARVO); in 2018, she became the first woman awarded the Charles L. Schepens Award from AAO. Recently, Dr. Miller was awarded the 2018 Lucien Howe Medal from the American Ophthalmological Society and the 2018 Gertrude D. Pyron Award from the American Society of Retinal Specialists.

Dimitri Azar, MD, MBA is the Chief Executive Officer of Twenty/Twenty Therapeutics, a joint venture established by Google/Verily and Santen. He is Distinguished Professor and BA Field chair of ophthalmic research and former Dean at the University of Illinois College of Medicine, where he pioneered the convergence of engineering and data science/artificial intelligence with basic and clinical medicine. Dimitri sits on the board of the Tear Film and Ocular Surface Society, the board of the Himalayan Cataract Project and the Verily SAB board. He also served as a non-executive director on the Boards of Novartis (2012-2019) and Verb Surgical (2015-2019).

He completed his residency and fellowship training at the Massachusetts Eye andEar Infirmary, Harvard Medical School. He then moved to the Johns Hopkins Wilmer Ophthalmological Institute as assistant professor and founding director of the refractive surgery service (1991-1996). He returned to the Mass Eye and Ear Infirmary as the Director of the Cornea, Refractive Surgery and Contact lens Services (1996-2006). He was named tenured Professor of Ophthalmology at Harvard Medical School (2003-2006) and senior scientist at the Schepens Eye Research Institute, before joining the University of Illinois as Head of the Ophthalmology Department (2006-2011), and later as Executive Dean (2011-2018).

He is an internationally recognized ophthalmic surgeon and a leader in basic science, corneal wound healing, angiogenesis, and clinically related vision research, making significant contributions to the treatment of corneal and anterior segment diseases and to advances in refractive surgery through mathematical analyses and applications of advanced optics. His basic science research on matrix metalloproteinases in corneal wound healing and angiogenesis was continually funded by the National Eye Institute R01 award between 1993 and 2021.

Dr. Azar received his MD from American University of Beirut and his MBA (with high distinction) from University of Chicago, Booth School of Business. He also holds an honorary doctoral degree from the University of Balamand, as well as an honorary master's degree from Harvard.

Dr. Azar is the author of more than 500 scientific articles and book chapters. He is the editor of 23 books in ophthalmology and holds more than 45 patents in ophthalmic pharmacology and bioengineering. He was named one of The Best Doctors in America or recognized among Castle Connolly’s Regional Top Doctors in America annually between 1994 and 2020. He is a member of the Beta Gamma Sigma Honor Society and has served as Trustee for the Chicago Medical Society and for the Association of Research and Vision in Ophthalmology, and President of the Chicago Ophthalmological Society. Dr. Azar has received numerous named lectures and leadership awards, including the Life Achievement award by the American Academy of Ophthalmology, the Lans Distinguished Award, the Castroviejo Award, and the University of Illinois at Chicago Scholar Award and Distinguished Professor Award.

Lucy Hwa-Yue Young, MD, PhD, FACS, is a multilingual vitreoretinal surgeon at Massachusetts Eye and Ear and associate professor of ophthalmology at Harvard Medical School. Dr. Young spent her childhood in Taiwan and Brazil before relocating to the United States, becoming fluent in English as well as Mandarin Chinese, Portuguese, and Spanish. She received her B.S. in molecular biology and M.D. from University of Wisconsin-Madison, then continued her training at Harvard University, where she earned her M.A. and Ph.D. degrees in biology. She conducted her ophthalmology residency and vitreoretinal fellowship at Massachusetts Eye andEar, Harvard Medical School. Dr. Young’s clinical and research interests encompass numerous vitreoretinal conditions, including trauma-related complications, infectious retinitis (particularly AIDS-related retinal infections), diabetic retinopathy, and macular degeneration. As a senior scientist at Massachusetts Eye and Ear, she is conducting several lines of investigation to improve the diagnosis and treatment of ocular toxoplasmosis. Dr. Young has co-authored more than 100 peer-reviewed research articles, reviews, and book chapters, and has been a member of the investigative team for more than 25 clinical trial reports. Ophthalmology education is also a major focus of Dr. Young’s activities where she serves as director of the Altschuler Ophthalmology Surgical Training Laboratory―a state-of-the-art training facility established in honor of Dr. Young. She also directs the Lancaster Course in Ophthalmology, which is based at Colby College in Waterville, Maine, and draws ophthalmology practitioners and trainees internationally. In addition to excellence in teaching, mentoring, and research, Dr. Young is recognized in Castle Connolly’s Top Doctors since 2008 and Boston Magazine’s Top Doctors since 2017.

"Sobre este t�tulo" puede pertenecer a otra edici�n de este libro.

Descripci�n de la librer�a

Hello! Ria Christie Collections is an online venture that was initially set up in 2012 to sell books. We do not have a physical high street store. We are professional online booksellers. We only sell brand new books in perfect condition that we source from various suppliers and the publishers. Primarily, our aim is to provide an excellent service to all our customers. We always work as a team to achieve this. Our other objectives are to: 1. Ensure that all our products reach their destination quickly in a safe and secure manner 2. Answer to all our customer queries within 24 hours 3. Ensure that our customers are happy with their purchases 4. Provide all the items at a competitive price 5. Always listen to our customers Ria Christie Collections is not a registered company. It is a Sole Trader venture. Other key information is shown below: Contact Person Name: Rakesh Luchmun (Mr) Storefront Name: Ria Christie Collections Place of Establishment Address: Suite B; ARUN House; ARUN Building Arundel Road Uxbridge UB8 2RR United Kingdom E-Mail Address: riachristie@hotmail.co.uk VAT Number: GB 160 5650 25 We always work hard and aim to comply with all of Abebooks Policies. If you have any issues, please do not hesitate to write to us whether before or after a purchase. We promise to reply to you promptly and, in any case, within 24 hours. Thank you kindly! Yours sincerely Mr Rakesh Luchmun (Founder) and the Ria Christie Collections Team

Ver la p�gina web de la librer�a

Informaci�n empresarial del vendedor

Ryefield Investments Limited
175 Pield Heath Road, Uxbridge, UB8 3NL, United Kingdom

Condiciones de venta y env�o

Condiciones de venta

All Returns and Refund are as per Abebooks policies.

Derecho al desistimiento

Si es un consumidor, puede rescindir el contrato de acuerdo con lo siguiente. Por consumidor se entiende cualquier persona f�sica que act�e con fines ajenos a su actividad comercial, empresarial, oficio o profesi�n.

Informaci�n sobre el derecho de desistimiento

Derecho legal de desistimiento

Tiene derecho a rescindir este contrato en un plazo de 14 d�as sin dar ning�n motivo.

El periodo de desistimiento vencer� a los 14 d�as desde que usted, o un tercero que no sea el transportista e indicado por usted, adquiera la posesi�n f�sica del �ltimo bien o del �ltimo lote o pieza.

Para ejercer el derecho de desistimiento, complete de forma electr�nica y env�e una declaraci�n clara en nuestro sitio web, desde "Mis compras" en "Mi cuenta". Le enviaremos sin demora un acuse de recibo de dicho desistimiento a trav�s de un soporte duradero (por ejemplo, por correo electr�nico).

Para cumplir con el plazo de desistimiento, basta con que env�e su comunicaci�n relativa al ejercicio del derecho de desistimiento antes de que venza el periodo de desistimiento.

Efectos del desistimiento

Si rescinde este contrato, le reembolsaremos todos los pagos que hayamos recibido de usted, incluidos los gastos de env�o (excepto los gastos adicionales que surjan si elige un tipo de env�o que no sea el tipo de env�o est�ndar m�s econ�mico que ofrecemos).

Podemos hacer una deducci�n del reembolso por la p�rdida de valor de cualquier bien suministrado, si la p�rdida es el resultado de una manipulaci�n innecesaria por su parte.

Efectuaremos el reembolso sin demoras indebidas y, a m�s tardar, 14 d�as despu�s de que se nos informe de su decisi�n de rescindir este contrato.

Efectuaremos el reembolso utilizando el mismo medio de pago que utiliz� para la transacci�n inicial, a menos que haya acordado expresamente lo contrario; en cualquier caso, no incurrir� en ning�n cargo como resultado de dicho reembolso.

Podremos retener el reembolso hasta que hayamos recibido los bienes o hasta que nos haya presentado una prueba de que los ha devuelto, lo que ocurra primero.

Deber� devolver los bienes o entregarlos a Ria Christie Collections, Uxbridge, United Kingdom, sin demoras indebidas y, en cualquier caso, en un plazo m�ximo de 14 d�as a partir del d�a en que nos comunique su desistimiento del presente contrato. El plazo se cumple si devuelve la mercanc�a antes de que venza el periodo de 14 d�as. Tendr� que asumir los gastos directos de devoluci�n de los bienes. Usted solo es responsable de la disminuci�n del valor de los bienes como resultado de una manipulaci�n distinta a la necesaria para establecer la naturaleza, las caracter�sticas y el funcionamiento de los bienes.

Excepciones al derecho de desistimiento

El derecho de desistimiento no se aplica a lo siguiente:

La entrega de peri�dicos, diarios o revistas, con la excepci�n de los contratos de suscripci�n; y
El suministro de contenido digital que no se proporcione en un soporte tangible (por ejemplo, en un CD o DVD) si, al hacer el pedido, acept� que pod�amos empezar a entregarlo y que no podr�a desistir una vez iniciada la entrega.

Condiciones de env�o

Orders usually ship within 2 business days. If your book order is heavy or oversized, we may contact you to let you know extra shipping is required. Thank you!

Tarifas de env�o de Reino Unido a Estados Unidos de America

Tarifas de env�o de Reino Unido a Estados Unidos de America
Cantidad del pedido	De 6 a 12 d�as h�biles	De 6 a 12 d�as h�biles
Primer art�culo	EUR 14.00	EUR 14.00

Los plazos de entrega los establecen los vendedores y var�an seg�n el transportista y la ubicaci�n. Los pedidos que pasan por la aduana pueden sufrir retrasos y los compradores son responsables de los aranceles o tarifas asociadas. Los vendedores pueden ponerse en contacto con usted en relaci�n con cargos adicionales para cubrir cualquier aumento en los costes de env�o de los art�culos.